Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel

Background. The aim of this paper was to evaluate the activity and tolerability of docetaxel (D) and bevacizumab (Bev) in patients with metastatic castrate-resistant prostate cancer (CRPC) previously exposed to D. Methods. Treatment consisted of D 30 mg/m2 i.v. for four consecutive weekly administra...

Full description

Bibliographic Details
Main Authors: Filippo Francini, Alessandra Pascucci, Edoardo Francini, Gianluca Bargagli, Raffaele Conca, Antonella Licchetta, Giandomenico Roviello, Ignazio Martellucci, Giorgio Chiriacò, Salvatora Tindara Miano, Giuseppe Marzocca, Antonio Manganelli, Roberto Ponchietti, Vinno Savelli, Roberto Petrioli
Format: Article
Language:English
Published: Hindawi Limited 2011-01-01
Series:Prostate Cancer
Online Access:http://dx.doi.org/10.1155/2011/258689

Internet

http://dx.doi.org/10.1155/2011/258689

Similar Items